In the early 1980s, Neill Walsdorf, Sr., Mission Chairman, Chief Executive Officer, and son of founder H.N. "Wally" Walsdorf, was diagnosed with kidney stone disease. He quickly discovered existing treatment options were limited. To help develop much-needed therapies, Mission funded The Neill Walsdorf Sr. Biotechnology Center in Mineral Metabolism at the University of Texas Southwestern Medical Center. This research center has produced leading drugs and devices to diagnose, treat, and prevent kidney stones and osteoporosis, as well as alleviate discomfort associated with urinary tract infections (UTIs) and interstitial cystitis.
Mission Pharmacal's pioneering efforts in the medical management of kidney stone disease paved the way for the company's broadening dedication to a variety of urologic conditions. We offer a number of highly effective prescription options for both urological therapeutic treatment and urological disease.
in 2013, Mission took its commitment to delivering urology solutions to the next level with the launch of a dedicated specialty sales team solely focused on urology products. Beyond just the urologic conditions themselves, Mission has been instrumental in helping to alleviate some of the key side effects, such as dry mouth, that are associated with many urology medications.
Mission Pharmacal treasures this rare determination and purposeful focus on providing treatment and relief for kidney stone disease.